Holly Meany, MD
- Oncologist
- Director, Solid Tumor Program
- Director, Hematology-Oncology Fellowship Program
-
- Fellowship Program, Pediatric Hematology/Oncology, Children's National Medical Center, Washington, DC (2006)
- Residency Program, General Pediatrics, Children's Hospital of Columbus, Columbus, OH (2003)
- Internship Program, General Pediatrics, Children's Hospital of Columbus, Columbus, OH (2001)
- MD, The Ohio State University College of Medicine, Columbus, OH (2000)
- BS, The College of William & Mary, Williamsburg, VA (1995)
-
Holly Meany, MD, is a pediatric oncologist and director of the Solid Tumor Program in the Division of Oncology at Children’s National Hospital as well as an associate professor of Pediatrics at the George Washington University. Her clinical research and initial efforts in the laboratory have focused on early phase clinical trial design, study execution and pharmacokinetic analysis to develop new therapeutic agents for the treatment of pediatric malignancies. Dr. Meany has led several investigator-initiated phase 1 clinical trials in pediatric solid tumors and acted as a co-investigator for industry sponsored trials at Children’s National. As a member of the Children’s Oncology Group Neuroblastoma Disease Committee, she led a group-wide phase 3 study treating patients with non-high-risk neuroblastoma and is vice chair of a phase 3 high-risk neuroblastoma trial currently under review.
Dr. Meany has an interest and experience utilizing immunotherapy for pediatric cancers having completed a phase 1 trial of antigen specific cytotoxic T cells in patients with relapsed or refractory solid tumors. She leads a study combining antigen specific T cells with a B7H3 CAR T cell in patients with relapsed embryonal cancers as part of an international collaboration.
As the Pediatric Hematology-Oncology Fellowship program director at Children’s National, Dr. Meany oversees 12 fellows and is involved in trainee education, program development and mentoring.
